The growing prevalence of several cardiovascular diseases such as atrial fibrillation, around the world, is driving the anticoagulant reversal drugs market. In addition, a steady rise in the geriatric population is also playing an eminent role in market expansion. Of late, the incidence of bleeding disorders has also been growing at a raced rate. Bleeding disorders can lead to excessive bleeding inside and outside the patient’s body. Such situations demand the use of anticoagulants hence increasing the need for anticoagulant reversal medications during uncontrolled bleeding. The market is further augmented by key factors such as the approval and introduction of novel medicines, and a surge in the frequency of indications for anticoagulant therapy. As a result of these notable factors, the global anticoagulant reversal drugs market is expected to witness sound expansion over the forecast period. 

 

For More Industry Insight Read: https://www.fairfieldmarketresearch.com/report/anticoagulant-reversal-drugs-market

 

Burgeoning Rates of Gastrointestinal (GI) Hemorrhages and Intracranial Hemorrhage (ICH) Drives Anticoagulant Reversal Drugs Market Growth 

 

In the recent past, the number of Gastrointestinal (GI) Hemorrhages and Intracranial Haemorrhages (ICH) cases has been rising at a raced rate. This can be mainly attributed to poor GI absorption, which drastically increases local drug levels. Anticoagulant reversal medicines are used to prevent excessive bleeding in patients suffering from these conditions. This has led to the growing prescription of direct oral anticoagulants (DOAC). DOAC are anticoagulation pharmacotherapy used for the prevention of thrombosis in several cardiovascular conditions. Such a scenario is poised to create novel growth and new revenue opportunities for the global anticoagulant reversal drugs market in the upcoming years. 

 

Idarucizumab to Gain Prominence in Anticoagulant Reversal Drugs Market

 

The growing accessibility of anticoagulation reversal medications has led to medical experts towards these therapeutic medicines. The increased adoption of Idarucizumab is directly coinciding with the expansion of the global anticoagulant reversal drugs market. Idarucizumab is prescribed to patients on Pradaxa or who are taking dabigatran post an urgent surgery or life-threatening bleeding case. Recently, it has got the approval by FDA as a reversal agent for the anticoagulant Pradaxa. Moreover, its excellent specificity and efficacy has contributed to its rising popularity among healthcare experts. This, in turn, is projected to unlock tremendous growth opportunities for the global anticoagulant reversal drugs market. 

 

Get a Sample Copy/TOC of the Anticoagulant Reversal Drugs Market Report: https://www.fairfieldmarketresearch.com/report/strapping-machine-market/request-toc

 

North America Reigns Supreme in Anticoagulant Reversal Drugs Market with Technologically Advanced Health Infrastructure 

 

North America is expected to maintain its lead in the global anticoagulant reversal drugs market. The region’s cutting-edge healthcare infrastructure can be credited majorly for this dominance. That said, the direct reimbursement policies in the region also contribute to market growth. Of late, the United States has been recording a growing number of bleeding disorders (VWD) cases such as Hemophilia A and B, and cardiovascular illnesses. The cumulative force of these factors is anticipated to unfurl substantial business opportunities for the anticoagulant reversal drugs market in North America. 

 

Prominent Market Players 

 

Some of the major players in the anticoagulant reversal drugs market include Boehringer Ingelheim, Portola Pharmaceuticals, Bausch Health Companies Inc., Mundipharma International Limited, CSL Behring, Dr. Reddy's Laboratories, Octapharma AG, Pfizer, Inc., AMAG Pharmaceuticals, Inc., SGPharma Pvt. Ltd., Ltd., Fresenius Kabi AG, Alps Pharmaceutical Ind. Co., and Hisamitsu Pharmaceutical Co., Inc.

 

Latest Trending Reports:

 

  1. Pet Utility Products Market Global Industry Analysis (2018 - 2021), Growth Trends, and Market Forecast (2022-2029) - https://www.openpr.com/news/2872611/pet-utility-products-market-growth-prediction-investment

 

  1. Phosphoric Acid Market Global Industry Analysis (2018 - 2021), Growth Trends, and Market Forecast (2022 -2029)- https://www.openpr.com/news/2872602/phosphoric-acid-market-analysis-by-industry-value-marketsize

 

  1. Silver Sulfate Market Global Industry Analysis (2018 - 2021), Growth Trends, and Market Forecast (2022 - 2029)- https://www.openpr.com/news/2872595/fairfieldmarket-research-projects-robust-growth-for-silver

 

  1. Smart Insulin Pens Market Global Industry Analysis (2018 - 2021), Growth Trends, and Market Forecast (2022 - 2029)- https://www.openpr.com/news/2872576/smart-insulin-pens-market-to-ride-the-wave-of-increasing-focus

 

  1. Strapping Machine Market Global Industry Analysis (2018 - 2021), Growth Trends, and Market Forecast (2022 - 2029)- https://www.openpr.com/news/2872565/fairfieldmarket-research-predicts-strong-growth-for-strapping

 

About Us 

Fairfield Market Research is a UK-based market research provider. Fairfield offers a wide spectrum of services, ranging from customized reports to consulting solutions. With a strong European footprint, Fairfield operates globally and helps businesses navigate through business cycles, with quick responses and multi-pronged approaches. The company values an eye for insightful take on global matters, ably backed by a team of exceptionally experienced researchers. With a strong repository of syndicated market research reports that are continuously published & updated to ensure the ever-changing needs of customers are met with absolute promptness. 

 

Contact 

Fairfield Market Research  

London, UK 

UK +44 (0)20 30025888     

USA (Toll-free) +1 (844) 3829746  

Web: https://www.fairfieldmarketresearch.com/  

Email: [email protected] 

Follow Us: LinkedIn